Process, resource and success factors associated with chimeric antigen receptor T-cell therapy for multiple myeloma.

Background: Chimeric antigen receptor T-cell (CAR-T) therapy represents a new frontier in multiple myeloma. It is important to understand critical success factors (CSFs) that may optimize its use in this therapeutic area. Methods: We estimated the CAR-T process using time-driven activity-based costing. Information was obtained through interviews at four US oncology centers and with payer representatives, and through publicly available data. Results: The CAR-T process comprises 13 steps which take 177 days; it was estimated to include 46 professionals and ten care settings. CSFs included proactive collaboration, streamlined reimbursement and CAR-T administration in alternative settings when possible. Implementing CSFs may reduce episode time and costs by 14.4 and 13.2%, respectively. Conclusion: Our research provides a blueprint for improving efficiencies in CAR-T therapy, thereby increasing its sustainability for multiple myeloma.

[1]  S. Fanti,et al.  Real World Evidence of CAR T-Cell Therapies for the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: A Monocentric Experience , 2021, Cancers.

[2]  R. Rajkumar,et al.  Setting the Stage for the Next 10 Years of Health Care Payment Innovation. , 2021, JAMA.

[3]  A. Navathe,et al.  Association of Patient Outcomes With Bundled Payments Among Hospitalized Patients Attributed to Accountable Care Organizations , 2021, JAMA health forum.

[4]  K. Bozic,et al.  Editorial Commentary: The Value of Time-Driven, Activity-Based Costing in Health Care Delivery. , 2021, Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association.

[5]  W. Chng,et al.  CAR T-cell therapy in multiple myeloma: more room for improvement , 2021, Blood Cancer Journal.

[6]  A. Goy,et al.  Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia , 2021, Journal for ImmunoTherapy of Cancer.

[7]  Zahra Mahmoudjafari,et al.  Chimeric Antigen Receptor T Cell Therapy: A Comprehensive Review of Clinical Efficacy, Toxicity, and Best Practices for Outpatient Administration. , 2021, Transplantation and cellular therapy.

[8]  J. Burmeister,et al.  Examining the Financial Impact of Altered Fractionation in Breast Cancer: An Analysis Using Time-Driven Activity-Based Costing. , 2021, Practical radiation oncology.

[9]  He Huang,et al.  Novel progresses of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma. , 2021, Stem cell investigation.

[10]  Z. Berneman,et al.  Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma , 2020, Journal of Hematology & Oncology.

[11]  E. Makhni,et al.  Time-Driven Activity-Based Costing Provides a Lower and More Accurate Assessment of Costs in the Field of Orthopaedic Surgery as Compared to Traditional Accounting Methods. , 2020, Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association.

[12]  Matthew J. Frigault,et al.  Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. , 2020, Blood advances.

[13]  A. Zelenetz,et al.  Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies. , 2020, Blood advances.

[14]  J. Kochenderfer,et al.  CAR T cell therapies for patients with multiple myeloma , 2020, Nature Reviews Clinical Oncology.

[15]  Brian P. Cunningham,et al.  Time-Driven Activity-Based Costing: A Better Way to Understand the Cost of Caring for Hip Fractures , 2020, Geriatric orthopaedic surgery & rehabilitation.

[16]  A. Kishan,et al.  Time-Driven Activity-Based Costing Analysis of Telemedicine Services in Radiation Oncology , 2020, International Journal of Radiation Oncology*Biology*Physics.

[17]  Kristy L Marynak,et al.  Delay or Avoidance of Medical Care Because of COVID-19–Related Concerns — United States, June 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[18]  J. Chavez,et al.  Real world experience of approved chimeric antigen receptor T-cell therapies outside of clinical trials. , 2020, Current research in translational medicine.

[19]  E. Emanuel,et al.  Alternative Payment Models-Victims of Their Own Success? , 2020, JAMA.

[20]  Pamela Mazzocato,et al.  Time-driven activity-based costing for patients with multiple chronic conditions: a mixed-method study to cost care in a multidisciplinary and integrated care delivery centre at a university-affiliated tertiary teaching hospital in Stockholm, Sweden , 2020, BMJ Open.

[21]  Ana Paula Beck da Silva Etges,et al.  Advances in Value-Based Healthcare by the Application of Time-Driven Activity-Based Costing for Inpatient Management: A Systematic Review. , 2020, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[22]  T. Showalter,et al.  Time-driven activity-based costing of a novel form of CT-guided high-dose-rate brachytherapy intraoperative radiation therapy compared with conventional breast intraoperative radiation therapy for early stage breast cancer. , 2020, Brachytherapy.

[23]  P. Kefalas,et al.  Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries , 2020, Journal of market access & health policy.

[24]  D. Gomez,et al.  Evaluating single-institution resource costs of consolidative radiotherapy for oligometastatic non-small cell lung cancer using time-driven activity-based costing , 2019, Clinical and translational radiation oncology.

[25]  Véronique Nabelsi,et al.  Breast cancer treatment pathway improvement using time-driven activity-based costing. , 2019, The International journal of health planning and management.

[26]  J. Teagarden,et al.  Are Payers Ready, Willing, and Able to Provide Access to New Durable Gene Therapies? , 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[27]  Tyler R. McClintock,et al.  Time-Driven Activity-Based Costing in Urologic Surgery Cycles of Care. , 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[28]  M. Milone,et al.  An introduction to chimeric antigen receptor (CAR) T‐cell immunotherapy for human cancer , 2019, American journal of hematology.

[29]  A. Sadosty,et al.  A Time-Driven Activity-Based Costing Analysis of Emergency Department Scribes , 2019, Mayo Clinic proceedings. Innovations, quality & outcomes.

[30]  C. Polanczyk,et al.  Activity-Based Costing and Time-Driven Activity-Based Costing for Assessing the Costs of Cancer Prevention, Diagnosis, and Treatment: A Systematic Review of the Literature. , 2018, Value in health regional issues.

[31]  K. Gromov,et al.  Time-driven activity-based cost of outpatient total hip and knee arthroplasty in different set-ups , 2018, Acta orthopaedica.

[32]  Sophie Hoozée,et al.  A Comparison of Activity-Based Costing and Time-Driven Activity-Based Costing , 2018 .

[33]  Ping-Pin Zheng,et al.  CAR T cell therapies : ice bucket challenges on glaring safety risks and long-term impacts , 2018 .

[34]  Mitchell H. Tsai,et al.  Using Time-Driven Activity-Based Costing as a Key Component of the Value Platform: A Pilot Analysis of Colonoscopy, Aortic Valve Replacement and Carpal Tunnel Release Procedures , 2018, Journal of clinical medicine research.

[35]  S. Beriwal,et al.  Time-Driven Activity-Based Costing in Oncology: A Step in the Right Direction. , 2018, International journal of radiation oncology, biology, physics.

[36]  George Keel,et al.  Time-driven activity-based costing in health care: A systematic review of the literature. , 2017, Health policy.

[37]  Vivian S. Lee,et al.  Dissecting Costs of CT Study: Application of TDABC (Time-driven Activity-based Costing) in a Tertiary Academic Center. , 2017, Academic radiology.

[38]  M. Ridderstråle.  Comparison Between Individually and Group-Based Insulin Pump Initiation by Time-Driven Activity-Based Costing , 2017, Journal of diabetes science and technology.

[39]  G. Jérôme,et al.  Rethinking the cost of healthcare in low-resource settings: the value of time-driven activity-based costing , 2016, BMJ Global Health.

[40]  Anand M Prabhakar,et al.  Time-Driven Activity-Based Costing in Emergency Medicine. , 2016, Annals of emergency medicine.

[41]  U. Siebert,et al.  Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics , 2016, PloS one.

[42]  R. Baggaley,et al.  Patient population with multiple myeloma and transitions across different lines of therapy in the USA: an epidemiologic model , 2016, Pharmacoepidemiology and drug safety.

[43]  Xue Song,et al.  Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States , 2016, Current medical research and opinion.

[44]  K. Bozic,et al.  Time-driven Activity-based Costing More Accurately Reflects Costs in Arthroplasty Surgery , 2016, Clinical orthopaedics and related research.

[45]  William Hsu,et al.  Utilizing time‐driven activity‐based costing to understand the short‐ and long‐term costs of treating localized, low‐risk prostate cancer , 2015, Cancer.

[46]  A Milstein,et al.  Time-driven activity-based costing of multivessel coronary artery bypass grafting across national boundaries to identify improvement opportunities: study protocol , 2015, BMJ Open.

[47]  A. Kudrin.  Reimbursement challenges with cancer immunotherapeutics , 2012, Human vaccines & immunotherapeutics.

[48]  R. Kaplan,et al.  Time-driven activity-based costing. , 2003, Harvard business review.